FTSE 100 news / Companies and sectors / GSK / 1 October 2026
GSK (GSK): news on Thursday 1 October 2026
+5.0 positive
Coverage was mostly positive, centred on GSK's progress with Wave's siRNA liver programme, continued Gates funding for TB research and a Jefferies view that its cancer pipeline is undervalued. Some share price pieces noted a pullback and weak trading, which held the score back.
What drove it
- Wave siRNA programme
- Gates TB funding
- oncology pipeline
The 20 stories
- +10.0 GSK's cancer pipeline undervalued, says Jefferies after science chief chat
Jefferies says cancer pipeline undervalued. - +9.2 GSK stock: company announces oncology deal and positive Jideytro data
Oncology deal and positive Jideytro data. - +8.3 GSK (NYSE:GSK): You Know It For Vaccines, But It Is Reinventing Itself as a Precision Cancer Player
Positive view of GSK's shift to precision oncology. - +7.5 Does GSK (LSE:GSK) Have Fresh Momentum As London Pharma Gets A Lift From Cancer Dealmaking With FTSE 100 In Focus?
Pharma lifted by cancer dealmaking, GSK in focus. - +6.7 GSK (LSE:GSK) Gets Extended Gates Funding For Tuberculosis Drug Research
Extended Gates funding for tuberculosis drug research. - +6.7 GSK (LSE:GSK) Expands TB Research as Gates Funding Continues
Continued Gates funding supports GSK's TB research expansion. - −6.7 GSK holds near daily low as support pressure weighs on recovery attempt
Shares struggling near daily low. - +5.8 GSK continues to stock up on Wave's RNA drugs with liver-focused program
GSK building RNA drug portfolio with liver program. - +5.8 Wave Life announces GSK’s selection of siRNA program to transition to GSK
GSK advances siRNA program from Wave collaboration. - −5.8 What's behind GSK's latest share pullback?
Coverage of GSK share pullback. - +5.0 GSK selects Wave Life Sciences hepatology candidate By Investing.com
GSK selects Wave hepatology candidate. - +5.0 GSK Taps Wave Life Sciences’ siRNA Program, Triggering $12M Milestone Payment
GSK taps Wave siRNA program, pipeline progress. - +5.0 Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
GSK selects siRNA program for further development. - +5.0 Wave Life Sciences Announces GSK Advances Hepatology Candidate from SpiNA siRNA Collaboration
GSK advances hepatology candidate from collaboration. - +4.7 GSK selected a liver candidate for development, triggering $12 million for Wave.
GSK picks liver candidate for development. - +4.2 Wave Life Sciences stock gets a USD 12.0 million GSK boost
GSK selects Wave program, pipeline progress; milestone paid by GSK. - +3.3 Wave to receive $12M milestone from GSK (WVE:NASDAQ)
Milestone payable to Wave reflects GSK program progress. - +1.7 Can GSK shares outperform FTSE 100 index over the long run?
Long-term performance discussion, mildly neutral. - 0.0 GSK (LSE:GSK) The Latest Update Raises A Bigger Question
Vague analysis piece, neutral. - 0.0 GSK Pharma stock enters a results blackout before Q2 FY27
Routine results blackout notice, neutral.
GSK: every day · Pharma and healthcare on 1 October 2026 · FTSE 100 overview for the day